PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.

Cells · 2021 · PMC8151045 · PMID 34068762

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Supporting the role of LAG-3 expressing cells contributing to the development of a permissive TME in cHL, a clinical cohort were described in which high numbers of LAG-3 + TILs within the diagnostic biopsy showed a trend for inferior outcome when treated with ABVD (Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) chemotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.